Skip to content

Pioneering new horizons in immunology to deliver life-changing therapies.

Our lead program barzolvolimab is a humanized monoclonal antibody inhibitor of KIT, a key receptor tyrosine kinase required for the function and survival of mast cells, which play a central role in the onset and progression of many severe inflammatory, allergic and autoimmune diseases. By targeting a core pathological driver of these diseases, we have designed barzolvolimab with the potential to be a best-in-class treatment option and improve the lives of patients.

Learn More

Our Science

Driven by our deep and longstanding experience developing antibody-based immunotherapies, Celldex’s proprietary antibody programs and technologies are supported by robust in-house capabilities, enabling the optimized discovery and development of innovative scientific programs.

Learn More

Audience watching a panel discussion on stage at a conference or event
Events & Presentations

View our upcoming events and recent presentations.

Learn More

Scientist using a pipette to transfer liquid into a small lab tube while wearing purple gloves
Clinical Trials

Get more information on Celldex’s ongoing clinical studies, including information about how to enroll.

Learn More

A scientist in a blue lab coat and green gloves using a pipette in a laboratory setting.
Careers

Celldex is always looking for passionate and talented individuals to join our team.

Careers

Top